The document implies the creation of a working group between the Ministry of Investment and Foreign Trade of the Republic of Uzbekistan, the Ministry of Health of the Republic of Uzbekistan and the Geropharm company to work out a project to localize insulin production in Uzbekistan.
The implementation of the project will significantly increase the availability of a number of vital medicines for people with diabetes mellitus and will be an important step in reducing the dependence of the Uzbek healthcare system on the import of these drugs, ensuring drug safety and developing biotechnological production in the country.
In accordance with the document, the Ministry of Investments and Foreign Trade of Uzbekistan will provide comprehensive support to the Russian manufacturer in resolving issues related to the implementation of the project. In the near future, the parties will develop and approve a "roadmap" for the practical implementation of the project, which includes specific measures and deadlines for their implementation, the press service of the MIVT of the Republic of Uzbekistan reports.
For reference: Geropharm LLC is a leader among Russian developers and manufacturers of biotechnological drugs in the CIS and EAEU countries. The company exports high-tech products in the field of endocrinology. Geropharm insulins are in high demand in the market of Uzbekistan and Central Asian countries.
